A multiomic liquid biopsy company applying next generation proteomics to early cancer detection.
Proteins can serve as a potent marker of cell state and disease but have been largely underutilized in liquid biopsy due to limitations in their isolation and detection relative to genomics methods. As a spinout of one of the premiere proteomics companies on the market today, Seer ($SEER), PrognomiQ is leveraging Seer’s cutting-edge Proteograph technology to perform analysis of the human proteome at greater depth than their competitors and identify cancer-associated protein biomarkers within blood. By integrating these markers with multiomics data, they can then construct highly sensitive tests for early cancer detection. PrognomiQ’s first product will be an early detection assay for non-small cell lung cancer (NSCLC), followed by similar tests for pancreatic and colorectal cancers.